Free Trial
→ I’d rather trade news like this than gamble on hype (From Timothy Sykes) (Ad) Free ABT Stock Alerts

Abbott Laboratories (ABT) Financials

Abbott Laboratories logo
$127.32 +1.13 (+0.90%)
Closing price 08/1/2025 03:59 PM Eastern
Extended Trading
$127.35 +0.03 (+0.02%)
As of 08/1/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for Abbott Laboratories

Annual Income Statements for Abbott Laboratories

This table shows Abbott Laboratories' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 4,423 1,400 477 2,368 3,687 4,495 7,071 6,933 5,723 13,402
Consolidated Net Income / (Loss)		 4,423 1,400 477 2,368 3,687 4,495 7,071 6,933 5,723 13,402
Net Income / (Loss) Continuing Operations		 2,606 1,063 353 2,334 3,687 4,471 7,071 6,933 5,723 13,402
Total Pre-Tax Income 		3,183 1,413 2,231 2,873 4,077 4,968 8,211 8,306 6,664 7,013
Total Operating Income		 2,867 3,026 1,564 3,650 4,532 5,357 8,425 8,362 6,478 6,825
Total Gross Profit		 11,658 11,759 14,981 17,872 18,673 19,605 24,538 24,511 22,134 23,244
Total Revenue		 20,405 20,853 27,390 30,578 31,904 34,608 43,075 43,653 40,109 41,950
Operating Revenue		 20,405 20,853 27,390 30,578 31,904 34,608 43,075 43,653 40,109 41,950
Total Cost of Revenue		 8,747 9,094 12,409 12,706 13,231 15,003 18,537 19,142 17,975 18,706
Operating Cost of Revenue		 8,747 9,094 12,409 12,706 13,231 15,003 18,537 19,142 17,975 18,706
Total Operating Expenses		 8,791 8,733 13,417 14,222 14,141 14,248 16,113 16,149 15,656 16,419
Selling, General & Admin Expense		 6,785 6,736 9,182 9,744 11,701 9,696 11,324 11,248 10,949 11,697
Research & Development Expense		 1,405 1,447 2,260 2,300 2,440 2,420 2,742 2,888 2,741 2,844
Amortization Expense		 601 550 1,975 2,178 - 2,132 2,047 2,013 1,966 1,878
Total Other Income / (Expense), net		 316 -1,613 667 -777 -455 -389 -214 -56 186 188
Interest Expense		 163 431 904 993 733 546 533 558 637 559
Interest & Investment Income		 105 99 124 105 94 46 43 183 385 344
Other Income / (Expense), net		 374 -1,281 1,447 111 184 111 276 319 438 403
Income Tax Expense		 577 350 1,878 539 390 497 1,140 1,373 941 -6,389
Basic Earnings per Share		 $2.94 $0.94 $0.27 $1.34 $2.07 $2.52 $3.97 $3.94 $3.28 $7.67
Weighted Average Basic Shares Outstanding		 1.50B 1.48B 1.74B 1.76B 1.77B 1.77B 1.78B 1.75B 1.74B 1.74B
Diluted Earnings per Share		 $2.92 $0.94 $0.27 $1.33 $2.06 $2.50 $3.94 $3.91 $3.26 $7.64
Weighted Average Diluted Shares Outstanding		 1.51B 1.48B 1.75B 1.77B 1.78B 1.79B 1.79B 1.76B 1.75B 1.75B
Weighted Average Basic & Diluted Shares Outstanding		 1.50B 1.73B 1.75B 1.77B 1.76B 1.77B 1.76B 1.74B 1.74B 1.73B
Cash Dividends to Common per Share		 - - - - - - - $1.92 $2.08 $2.24

Quarterly Income Statements for Abbott Laboratories

This table shows Abbott Laboratories' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 1,435 1,033 1,318 1,375 1,436 1,594 1,225 1,302 1,646 9,229 1,325
Consolidated Net Income / (Loss)		 1,435 1,033 1,318 1,375 1,436 1,594 1,225 1,302 1,646 9,229 1,325
Net Income / (Loss) Continuing Operations		 1,435 1,033 1,318 1,375 1,436 1,594 1,225 1,302 1,646 9,229 1,325
Total Pre-Tax Income 		1,758 1,320 1,562 1,636 1,671 1,795 1,436 1,607 1,940 2,030 1,778
Total Operating Income		 1,770 1,304 1,509 1,542 1,647 1,780 1,386 1,669 1,859 1,911 1,693
Total Gross Profit		 5,781 5,498 5,416 5,495 5,538 5,685 5,501 5,774 5,937 6,032 5,890
Total Revenue		 10,410 10,091 9,747 9,978 10,143 10,241 9,964 10,377 10,635 10,974 10,358
Operating Revenue		 10,410 10,091 9,747 9,978 10,143 10,241 9,964 10,377 10,635 10,974 10,358
Total Cost of Revenue		 4,629 4,593 4,331 4,483 4,605 4,556 4,463 4,603 4,698 4,942 4,468
Operating Cost of Revenue		 4,629 4,593 4,331 4,483 4,605 4,556 4,463 4,603 4,698 4,942 4,468
Total Operating Expenses		 4,011 4,194 3,907 3,953 3,891 3,905 4,115 4,105 4,078 4,121 4,197
Selling, General & Admin Expense		 2,731 2,973 2,762 2,740 2,723 2,724 2,959 2,936 2,895 2,907 3,061
Research & Development Expense		 782 725 654 715 672 700 684 698 713 749 716
Amortization Expense		 498 496 491 498 496 481 472 471 470 465 420
Total Other Income / (Expense), net		 -12 16 53 94 24 15 50 -62 81 119 85
Interest Expense		 141 154 153 159 166 159 141 140 142 136 131
Interest & Investment Income		 55 88 101 98 97 89 80 82 91 91 82
Other Income / (Expense), net		 74 82 105 155 93 85 111 -4.00 132 164 134
Income Tax Expense		 323 287 244 261 235 201 211 305 294 -7,199 453
Basic Earnings per Share		 $0.82 $0.59 $0.75 $0.79 $0.82 $0.92 $0.70 $0.74 $0.94 $5.29 $0.76
Weighted Average Basic Shares Outstanding		 1.75B 1.75B 1.74B 1.74B 1.74B 1.74B 1.74B 1.74B 1.74B 1.74B 1.74B
Diluted Earnings per Share		 $0.81 $0.59 $0.75 $0.78 $0.82 $0.91 $0.70 $0.74 $0.94 $5.26 $0.76
Weighted Average Diluted Shares Outstanding		 1.76B 1.76B 1.75B 1.75B 1.75B 1.75B 1.75B 1.75B 1.75B 1.75B 1.75B
Weighted Average Basic & Diluted Shares Outstanding		 1.74B 1.74B 1.74B 1.74B 1.74B 1.74B 1.74B 1.74B 1.73B 1.73B 1.74B
Cash Dividends to Common per Share		 - - - - $0.51 - - - $0.55 - $0.59

Annual Cash Flow Statements for Abbott Laboratories

This table details how cash moves in and out of Abbott Laboratories' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Change in Cash & Equivalents		 938 13,619 -9,329 -5,447 16 2,978 2,961 83 -2,986 720
Net Cash From Operating Activities		 2,966 3,203 5,570 6,300 6,136 7,901 10,533 9,581 7,261 8,558
Net Cash From Continuing Operating Activities		 2,966 3,203 5,570 6,300 6,136 7,901 10,533 9,581 7,261 8,558
Net Income / (Loss) Continuing Operations		 4,423 1,400 477 2,368 3,687 4,495 7,071 6,933 5,723 13,402
Consolidated Net Income / (Loss)		 4,423 1,400 477 2,368 3,687 4,495 7,071 6,933 5,723 13,402
Depreciation Expense		 871 803 1,046 1,100 1,078 1,195 1,491 1,254 1,277 1,340
Amortization Expense		 601 715 2,887 2,210 1,936 2,132 2,047 2,013 1,966 1,878
Non-Cash Adjustments To Reconcile Net Income		 -2,773 1,798 -755 770 766 971 695 900 770 1,155
Changes in Operating Assets and Liabilities, net		 -156 -1,513 1,915 -148 -1,331 -892 -771 -1,519 -2,475 -9,217
Net Cash From Investing Activities		 406 -248 -9,618 -1,356 -1,815 -2,215 -2,008 -1,740 -3,133 -2,338
Net Cash From Continuing Investing Activities		 406 -248 -9,618 -1,356 -1,815 -2,215 -2,008 -1,740 -3,133 -2,338
Purchase of Property, Plant & Equipment		 -1,110 -1,121 -1,135 -1,394 -1,638 -2,177 -1,885 -1,777 -2,202 -2,207
Acquisitions		 -235 -80 -17,183 -54 -170 -42 -187 0.00 -877 0.00
Purchase of Investments		 -4,933 -2,823 -210 -131 -103 -83 -173 -185 -159 -169
Divestitures		 230 25 6,042 48 48 58 134 48 40 1.00
Sale and/or Maturity of Investments		 6,402 3,709 2,833 73 21 10 77 152 43 28
Other Investing Activities, net		 52 42 35 102 27 19 26 22 22 9.00
Net Cash From Financing Activities		 -2,236 11,147 -5,281 -10,391 -4,289 -2,779 -5,494 -7,636 -7,091 -5,404
Net Cash From Continuing Financing Activities		 -2,236 11,147 -5,281 -10,391 -4,289 -2,779 -5,494 -7,636 -7,091 -5,404
Repayment of Debt		 -1,338 -1,949 -9,684 -12,459 -3,441 -1,342 -252 -706 -2,477 -760
Repurchase of Common Equity		 -2,237 -522 -117 -238 -718 -403 -2,299 -3,795 -1,227 -1,295
Payment of Dividends		 -1,443 -1,539 -1,849 -1,974 -2,270 -2,560 -3,202 -3,309 -3,556 -3,836
Issuance of Debt		 2,485 14,934 6,742 4,009 1,842 1,281 4.00 7.00 2.00 223
Other Financing Activities, net		 297 223 337 271 298 245 255 167 167 264
Effect of Exchange Rate Changes		 -198 -483 - - -16 71 -70 -122 -23 -96
Cash Interest Paid		 166 181 917 845 677 549 544 563 662 604
Cash Income Taxes Paid		 631 620 570 740 930 970 1,941 1,864 1,475 1,723

Quarterly Cash Flow Statements for Abbott Laboratories

This table details how cash moves in and out of Abbott Laboratories' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025
Net Change in Cash & Equivalents		 657 288 -721 -1,326 -1,126 187 -612 703 571 58 -1,084
Net Cash From Operating Activities		 2,780 2,326 1,143 1,203 1,877 3,038 1,025 1,960 2,705 2,868 1,417
Net Cash From Continuing Operating Activities		 2,780 2,326 1,143 1,203 1,877 3,038 1,025 1,960 2,705 2,868 1,417
Net Income / (Loss) Continuing Operations		 1,435 1,033 1,318 1,375 1,436 1,594 1,225 1,302 1,646 9,229 1,325
Consolidated Net Income / (Loss)		 1,435 1,033 1,318 1,375 1,436 1,594 1,225 1,302 1,646 9,229 1,325
Depreciation Expense		 317 311 315 302 328 332 333 334 331 342 336
Amortization Expense		 498 496 491 498 496 481 472 471 470 465 420
Non-Cash Adjustments To Reconcile Net Income		 123 330 281 132 117 240 304 141 117 593 289
Changes in Operating Assets and Liabilities, net		 407 156 -1,262 -1,104 -500 391 -1,309 -288 141 -7,761 -953
Net Cash From Investing Activities		 -484 -632 -462 -1,213 -634 -824 -425 -453 -594 -866 -470
Net Cash From Continuing Investing Activities		 -484 -632 -462 -1,213 -634 -824 -425 -453 -594 -866 -470
Purchase of Property, Plant & Equipment		 -467 -610 -380 -507 -560 -755 -398 -533 -556 -720 -484
Sale and/or Maturity of Investments		 - - - - - - - - - - 8.00
Other Investing Activities, net		 4.00 8.00 4.00 1.00 15 2.00 1.00 2.00 2.00 4.00 6.00
Net Cash From Financing Activities		 -1,543 -1,457 -1,410 -1,289 -2,340 -2,052 -1,176 -791 -1,576 -1,861 -2,055
Net Cash From Continuing Financing Activities		 -1,543 -1,457 -1,410 -1,289 -2,340 -2,052 -1,176 -791 -1,576 -1,861 -2,055
Repayment of Debt		 23 10 -42 11 -1,506 -940 -127 -61 42 -614 -1,037
Repurchase of Common Equity		 -798 -685 -540 -426 -2.00 -259 -226 -3.00 -751 -315 -280
Payment of Dividends		 -826 -823 -890 -890 -888 -888 -957 -961 -960 -958 -1,026
Issuance of Debt		 1.00 - - - - 1.00 - - 1.00 1.00 1.00
Other Financing Activities, net		 57 41 62 15 56 34 134 13 92 25 287
Effect of Exchange Rate Changes		 -96 51 8.00 - - 25 -36 -13 36 -83 24

Annual Balance Sheets for Abbott Laboratories

This table presents Abbott Laboratories' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Total Assets		 41,247 52,666 76,250 67,173 67,887 72,548 75,196 74,438 73,214 81,414
Total Current Assets		 14,155 26,776 20,147 14,632 15,667 20,441 24,239 25,224 22,670 23,656
Cash & Equivalents		 5,001 18,620 9,407 3,844 3,860 6,838 9,799 9,882 6,896 7,616
Short-Term Investments		 1,124 155 203 242 280 310 450 288 383 351
Accounts Receivable		 3,418 3,248 5,249 5,182 5,425 6,414 6,487 6,218 6,565 6,925
Inventories, net		 2,599 2,434 3,601 3,796 4,316 5,012 5,157 6,173 6,570 6,194
Prepaid Expenses		 - - 1,667 1,568 1,786 1,867 2,346 2,663 2,256 2,570
Plant, Property, & Equipment, net		 5,730 5,705 7,607 7,563 8,038 9,029 8,959 9,162 10,154 10,658
Plant, Property & Equipment, gross		 12,383 12,366 15,265 15,706 16,799 18,793 19,364 20,212 21,933 22,740
Accumulated Depreciation		 6,653 6,661 7,658 8,143 8,761 9,764 10,405 11,050 11,779 12,082
Total Noncurrent Assets		 21,362 20,185 48,496 44,978 44,182 43,078 41,998 40,052 40,390 47,100
Long-Term Investments		 4,041 2,947 883 897 883 821 816 766 799 886
Goodwill		 9,638 7,683 24,020 23,254 23,195 23,744 23,231 22,799 23,679 23,108
Intangible Assets		 5,562 4,539 21,473 18,942 17,025 14,784 12,739 10,454 8,815 6,647
Noncurrent Deferred & Refundable Income Taxes		 2,119 2,263 1,944 1,885 3,079 3,729 5,212 6,033 7,097 16,459
Total Liabilities & Shareholders' Equity		 41,247 52,666 76,250 67,173 67,887 72,548 75,196 74,438 73,214 81,414
Total Liabilities		 19,921 31,949 45,152 36,451 36,586 39,545 39,172 37,533 34,387 33,513
Total Current Liabilities		 9,186 6,660 8,912 9,012 10,863 11,907 13,105 15,489 13,841 14,157
Short-Term Debt		 3,130 1,325 714 207 1,478 220 754 2,251 1,080 1,500
Accounts Payable		 1,081 1,178 2,402 2,975 3,252 3,946 4,408 4,607 4,295 4,195
Accrued Expenses		 3,043 2,581 3,811 3,780 4,035 5,165 5,181 5,845 5,422 5,143
Dividends Payable		 383 391 489 563 635 798 831 887 955 1,024
Current Deferred & Payable Income Tax Liabilities		 430 188 309 305 226 362 306 343 492 594
Current Employee Benefit Liabilities		 746 752 1,187 1,182 1,237 1,416 1,625 1,556 1,597 1,701
Total Noncurrent Liabilities		 10,735 25,289 36,240 27,439 25,723 27,638 26,067 22,044 20,546 19,356
Long-Term Debt		 5,871 20,681 27,210 19,359 16,661 18,527 17,296 14,522 13,599 12,625
Other Noncurrent Operating Liabilities		 4,864 4,549 - - 9,062 9,111 8,771 7,522 6,947 6,731
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 21,326 20,717 31,098 30,722 31,301 33,003 36,024 36,905 38,827 47,901
Total Preferred & Common Equity		 21,211 20,538 30,897 30,524 31,088 32,784 35,802 36,686 38,603 47,664
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 21,211 20,538 30,897 30,524 31,088 32,784 35,802 36,686 38,603 47,664
Common Stock		 12,734 13,027 23,206 23,512 23,853 24,145 24,470 24,709 24,869 25,153
Retained Earnings		 25,757 25,565 23,978 24,560 25,847 27,627 31,528 35,257 37,554 47,261
Treasury Stock		 -10,622 -10,791 -10,225 - -10,147 -10,042 - - - -16,844
Accumulated Other Comprehensive Income / (Loss)		 -6,658 -7,263 -6,062 -7,586 -8,465 -8,946 -8,374 -8,051 -7,839 -7,906
Noncontrolling Interest		 115 179 201 198 213 219 222 219 224 237

Quarterly Balance Sheets for Abbott Laboratories

This table presents Abbott Laboratories' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025
Total Assets		 72,801 74,438 73,794 73,354 72,090 73,214 72,467 73,017 74,356 81,414 81,448
Total Current Assets		 24,845 25,224 24,377 23,505 22,664 22,670 22,376 23,119 23,802 23,656 23,153
Cash & Equivalents		 9,594 9,882 9,161 7,835 6,709 6,896 6,284 6,987 7,558 7,616 6,532
Short-Term Investments		 313 288 371 320 338 383 367 232 230 351 312
Accounts Receivable		 6,408 6,218 6,020 6,172 6,499 6,565 6,605 6,854 7,051 6,925 7,327
Inventories, net		 5,734 6,173 6,673 6,871 6,650 6,570 6,827 6,814 6,813 6,194 6,639
Prepaid Expenses		 2,796 2,663 2,152 2,307 2,468 2,256 2,293 2,232 2,150 2,570 2,343
Plant, Property, & Equipment, net		 8,689 9,162 9,282 9,449 9,552 10,154 10,107 10,233 10,621 10,658 10,932
Plant, Property & Equipment, gross		 19,306 20,212 20,605 20,926 21,111 21,933 22,055 22,061 22,857 22,740 23,418
Accumulated Depreciation		 10,617 11,050 11,323 11,477 11,559 11,779 11,948 11,828 12,236 12,082 12,486
Total Noncurrent Assets		 39,267 40,052 40,135 40,400 39,874 40,390 39,984 39,665 39,933 47,100 47,363
Long-Term Investments		 764 766 776 799 788 799 818 877 912 886 907
Goodwill		 22,284 22,799 22,927 23,258 23,277 23,679 23,383 23,308 23,658 23,108 23,359
Intangible Assets		 10,850 10,454 10,006 9,834 9,282 8,815 8,296 7,827 7,352 6,647 6,261
Noncurrent Deferred & Refundable Income Taxes		 5,369 6,033 6,426 6,509 6,527 7,097 7,487 7,653 8,011 16,459 16,836
Total Liabilities & Shareholders' Equity		 72,801 74,438 73,794 73,354 72,090 73,214 72,467 73,017 74,356 81,414 81,448
Total Liabilities		 36,917 37,533 36,562 35,950 34,396 34,387 33,424 33,457 34,328 33,513 32,384
Total Current Liabilities		 13,365 15,489 14,530 14,350 13,042 13,841 14,021 13,760 14,902 14,157 13,004
Short-Term Debt		 1,117 2,251 2,285 2,284 1,051 1,080 2,010 1,615 2,154 1,500 506
Accounts Payable		 4,133 4,607 4,167 4,211 3,961 4,295 4,178 4,125 4,034 4,195 4,214
Accrued Expenses		 5,475 5,845 5,758 5,334 5,347 5,422 5,220 5,071 5,427 5,143 5,600
Dividends Payable		 820 887 888 886 886 955 959 959 956 1,024 1,032
Current Deferred & Payable Income Tax Liabilities		 394 343 334 273 318 492 562 601 713 594 485
Current Employee Benefit Liabilities		 1,426 1,556 1,098 1,362 1,479 1,597 1,092 1,389 1,618 1,701 1,167
Total Noncurrent Liabilities		 23,552 22,044 22,032 21,600 21,354 20,546 19,403 19,697 19,426 19,356 19,380
Long-Term Debt		 15,297 14,522 14,615 14,562 14,477 13,599 12,576 13,139 12,825 12,625 12,736
Noncurrent Deferred & Payable Income Tax Liabilities		 8,255 - 7,417 7,038 6,877 - 6,827 6,558 6,601 - 6,644
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 35,884 36,905 37,232 37,404 37,694 38,827 39,043 39,560 40,028 47,901 49,064
Total Preferred & Common Equity		 35,675 36,686 37,010 37,174 37,481 38,603 38,810 39,318 39,796 47,664 48,811
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 35,675 36,686 37,010 37,174 37,481 38,603 38,810 39,318 39,796 47,664 48,811
Common Stock		 24,560 24,709 24,488 24,612 24,727 24,869 24,726 24,858 25,020 25,153 25,125
Retained Earnings		 35,115 35,257 35,868 36,355 36,920 37,554 38,011 38,354 39,056 47,261 47,715
Treasury Stock		 - - -15,307 -15,722 -15,686 - - -15,759 -16,476 -16,844 -16,612
Accumulated Other Comprehensive Income / (Loss)		 -9,445 -8,051 -8,039 -8,071 -8,480 -7,839 -8,166 -8,135 -7,804 -7,906 -7,417
Noncontrolling Interest		 209 219 222 230 213 224 233 242 232 237 253

Annual Metrics And Ratios for Abbott Laboratories

This table displays calculated financial ratios and metrics derived from Abbott Laboratories' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 0.78% 2.20% 31.35% 11.64% 4.34% 8.48% 24.47% 1.34% -8.12% 4.59%
EBITDA Growth		 13.38% -30.77% 112.81% 1.83% 9.32% 13.78% 39.16% -2.38% -14.97% 2.83%
EBIT Growth		 24.22% -46.16% 72.55% 24.91% 25.39% 15.95% 59.13% -0.23% -20.33% 4.51%
NOPAT Growth		 32.14% -3.02% -89.13% 1,098.25% 38.22% 17.63% 50.49% -3.80% -20.29% 134.44%
Net Income Growth		 93.65% -68.35% -65.93% 396.44% 55.70% 21.91% 57.31% -1.95% -17.45% 134.18%
EPS Growth		 95.97% -67.81% -71.28% 392.59% 54.89% 21.36% 57.60% -0.76% -16.62% 134.36%
Operating Cash Flow Growth		 -19.29% 7.99% 73.90% 13.11% -2.60% 28.76% 33.31% -9.04% -24.21% 17.86%
Free Cash Flow Firm Growth		 84.66% 0.33% -747.37% 119.64% -16.97% 7.72% 51.00% -10.05% -60.93% 86.12%
Invested Capital Growth		 -9.93% -11.44% 164.91% -6.05% -1.78% -1.05% -1.66% -0.48% 6.31% 16.85%
Revenue Q/Q Growth		 -0.70% 0.70% 8.98% 0.58% 1.75% 7.41% 1.81% -3.06% 0.38% 1.78%
EBITDA Q/Q Growth		 -0.59% 9.50% 3.15% 3.63% 3.34% 15.54% -0.42% -8.69% 5.01% 1.99%
EBIT Q/Q Growth		 0.03% 10.44% -6.78% 11.90% 5.76% 24.41% -0.78% -10.89% 7.44% 2.99%
NOPAT Q/Q Growth		 1.16% 2.76% -81.43% 190.04% 9.32% 26.98% -2.24% -12.68% 11.13% 129.00%
Net Income Q/Q Growth		 -3.03% 2.26% -77.32% 167.27% 12.00% 32.91% -2.39% -12.12% 10.87% 132.39%
EPS Q/Q Growth		 -4.26% 3.30% -78.91% 171.43% 11.96% 32.28% -2.23% -11.74% 10.88% 132.22%
Operating Cash Flow Q/Q Growth		 -12.14% 11.95% 9.22% 2.02% 11.87% 21.20% -6.49% -7.18% 10.87% -1.95%
Free Cash Flow Firm Q/Q Growth		 -82.50% 126.77% -30.39% 551.28% 32.18% 6.70% -14.56% -18.97% 138.07% 11.12%
Invested Capital Q/Q Growth		 0.00% -6.03% 10.80% -1.14% -2.96% -1.51% 1.18% 2.78% 0.24% 14.67%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 57.13% 56.39% 54.70% 58.45% 58.53% 56.65% 56.97% 56.15% 55.18% 55.41%
EBITDA Margin		 23.10% 15.65% 25.35% 23.12% 24.23% 25.41% 28.41% 27.37% 25.33% 24.90%
Operating Margin		 14.05% 14.51% 5.71% 11.94% 14.21% 15.48% 19.56% 19.16% 16.15% 16.27%
EBIT Margin		 15.88% 8.37% 10.99% 12.30% 14.78% 15.80% 20.20% 19.89% 17.24% 17.23%
Profit (Net Income) Margin		 21.68% 6.71% 1.74% 7.74% 11.56% 12.99% 16.42% 15.88% 14.27% 31.95%
Tax Burden Percent		 138.96% 99.08% 21.38% 82.42% 90.43% 90.48% 86.12% 83.47% 85.88% 191.10%
Interest Burden Percent		 98.21% 80.97% 74.10% 76.39% 86.45% 90.86% 94.37% 95.68% 96.36% 97.03%
Effective Tax Rate		 18.13% 24.77% 84.18% 18.76% 9.57% 10.00% 13.88% 16.53% 14.12% -91.10%
Return on Invested Capital (ROIC)		 10.69% 11.60% 0.74% 6.26% 9.02% 10.76% 16.41% 15.96% 12.36% 25.94%
ROIC Less NNEP Spread (ROIC-NNEP)		 448.14% 74.14% 3.71% 2.63% 6.17% 8.18% 14.51% 15.32% 14.60% 31.12%
Return on Net Nonoperating Assets (RNNOA)		 9.90% -4.94% 1.11% 1.40% 2.87% 3.22% 4.08% 3.05% 2.75% 4.97%
Return on Equity (ROE)		 20.59% 6.66% 1.84% 7.66% 11.89% 13.98% 20.49% 19.01% 15.11% 30.91%
Cash Return on Invested Capital (CROIC)		 21.14% 23.73% -89.65% 12.50% 10.81% 11.81% 18.08% 16.44% 6.24% 10.40%
Operating Return on Assets (OROA)		 7.86% 3.72% 4.67% 5.24% 6.98% 7.79% 11.78% 11.60% 9.37% 9.35%
Return on Assets (ROA)		 10.73% 2.98% 0.74% 3.30% 5.46% 6.40% 9.57% 9.27% 7.75% 17.33%
Return on Common Equity (ROCE)		 20.48% 6.61% 1.83% 7.61% 11.81% 13.89% 20.36% 18.90% 15.03% 30.74%
Return on Equity Simple (ROE_SIMPLE)		 20.85% 6.82% 1.54% 7.76% 11.86% 13.71% 19.75% 18.90% 14.83% 28.12%
Net Operating Profit after Tax (NOPAT)		 2,347 2,276 247 2,965 4,098 4,821 7,255 6,980 5,563 13,043
NOPAT Margin		 11.50% 10.92% 0.90% 9.70% 12.85% 13.93% 16.84% 15.99% 13.87% 31.09%
Net Nonoperating Expense Percent (NNEP)		 -437.45% -62.54% -2.97% 3.63% 2.85% 2.58% 1.90% 0.64% -2.24% -5.19%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - 13.00% 10.40% 21.03%
Cost of Revenue to Revenue		 42.87% 43.61% 45.30% 41.55% 41.47% 43.35% 43.03% 43.85% 44.82% 44.59%
SG&A Expenses to Revenue		 33.25% 32.30% 33.52% 31.87% 36.68% 28.02% 26.29% 25.77% 27.30% 27.88%
R&D to Revenue		 6.89% 6.94% 8.25% 7.52% 7.65% 6.99% 6.37% 6.62% 6.83% 6.78%
Operating Expenses to Revenue		 43.08% 41.88% 48.99% 46.51% 44.32% 41.17% 37.41% 36.99% 39.03% 39.14%
Earnings before Interest and Taxes (EBIT)		 3,241 1,745 3,011 3,761 4,716 5,468 8,701 8,681 6,916 7,228
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 4,713 3,263 6,944 7,071 7,730 8,795 12,239 11,948 10,159 10,446
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 2.68 2.39 2.86 3.77 4.55 5.54 6.60 4.99 4.83 4.09
Price to Tangible Book Value (P/TBV)		 9.44 5.91 0.00 0.00 0.00 0.00 0.00 53.32 30.51 10.90
Price to Revenue (P/Rev)		 2.78 2.36 3.23 3.76 4.43 5.24 5.49 4.19 4.65 4.65
Price to Earnings (P/E)		 12.83 35.12 185.24 48.59 38.36 40.38 33.43 26.40 32.57 14.56
Dividend Yield		 2.52% 3.11% 2.09% 1.71% 1.60% 1.41% 1.35% 1.79% 1.90% 1.96%
Earnings Yield		 7.79% 2.85% 0.54% 2.06% 2.61% 2.48% 2.99% 3.79% 3.07% 6.87%
Enterprise Value to Invested Capital (EV/IC)		 2.68 2.69 2.17 2.83 3.44 4.32 5.56 4.33 4.17 3.70
Enterprise Value to Revenue (EV/Rev)		 2.73 2.38 3.87 4.25 4.85 5.56 5.65 4.33 4.82 4.78
Enterprise Value to EBITDA (EV/EBITDA)		 11.82 15.21 15.26 18.36 20.02 21.89 19.90 15.83 19.02 19.21
Enterprise Value to EBIT (EV/EBIT)		 17.19 28.44 35.20 34.53 32.82 35.21 27.99 21.78 27.93 27.76
Enterprise Value to NOPAT (EV/NOPAT)		 23.73 21.80 428.31 43.79 37.76 39.93 33.57 27.09 34.73 15.39
Enterprise Value to Operating Cash Flow (EV/OCF)		 18.78 15.49 19.03 20.61 25.22 24.36 23.13 19.74 26.61 23.45
Enterprise Value to Free Cash Flow (EV/FCFF)		 12.00 10.66 0.00 21.94 31.49 36.36 30.47 26.30 68.77 38.38
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.42 1.06 0.90 0.64 0.58 0.57 0.50 0.45 0.38 0.29
Long-Term Debt to Equity		 0.28 1.00 0.88 0.63 0.53 0.56 0.48 0.39 0.35 0.26
Financial Leverage		 0.02 -0.07 0.30 0.53 0.47 0.39 0.28 0.20 0.19 0.16
Leverage Ratio		 1.92 2.23 2.49 2.32 2.18 2.18 2.14 2.05 1.95 1.78
Compound Leverage Factor		 1.88 1.81 1.84 1.77 1.88 1.98 2.02 1.96 1.88 1.73
Debt to Total Capital		 29.68% 51.51% 47.31% 38.91% 36.69% 36.23% 33.38% 31.25% 27.43% 22.77%
Short-Term Debt to Total Capital		 10.32% 3.10% 1.21% 0.41% 2.99% 0.43% 1.39% 4.19% 2.02% 2.42%
Long-Term Debt to Total Capital		 19.36% 48.41% 46.10% 38.50% 33.70% 35.80% 31.99% 27.05% 25.42% 20.35%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.38% 0.42% 0.34% 0.39% 0.43% 0.42% 0.41% 0.41% 0.42% 0.38%
Common Equity to Total Capital		 69.94% 48.07% 52.35% 60.70% 62.88% 63.35% 66.21% 68.34% 72.15% 76.85%
Debt to EBITDA		 1.91 6.74 4.02 2.77 2.35 2.13 1.47 1.40 1.44 1.35
Net Debt to EBITDA		 -0.25 0.09 2.51 2.06 1.70 1.23 0.57 0.49 0.65 0.50
Long-Term Debt to EBITDA		 1.25 6.34 3.92 2.74 2.16 2.11 1.41 1.22 1.34 1.21
Debt to NOPAT		 3.83 9.67 112.84 6.60 4.43 3.89 2.49 2.40 2.64 1.08
Net Debt to NOPAT		 -0.50 0.12 70.44 4.92 3.20 2.24 0.96 0.84 1.19 0.40
Long-Term Debt to NOPAT		 2.50 9.08 109.96 6.53 4.07 3.84 2.38 2.08 2.44 0.97
Altman Z-Score		 3.48 2.57 2.28 3.15 3.64 4.15 5.34 4.72 4.97 5.26
Noncontrolling Interest Sharing Ratio		 0.53% 0.70% 0.73% 0.65% 0.66% 0.67% 0.64% 0.60% 0.59% 0.53%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 1.54 4.02 2.26 1.62 1.44 1.72 1.85 1.63 1.64 1.67
Quick Ratio		 1.04 3.31 1.67 1.03 0.88 1.14 1.28 1.06 1.00 1.05
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 4,641 4,656 -30,145 5,919 4,914 5,294 7,994 7,191 2,809 5,229
Operating Cash Flow to CapEx		 267.21% 285.73% 490.75% 451.94% 374.60% 362.93% 558.78% 539.17% 329.75% 387.77%
Free Cash Flow to Firm to Interest Expense		 28.47 10.80 -33.35 5.96 6.70 9.70 15.00 12.89 4.41 9.35
Operating Cash Flow to Interest Expense		 18.20 7.43 6.16 6.34 8.37 14.47 19.76 17.17 11.40 15.31
Operating Cash Flow Less CapEx to Interest Expense		 11.39 4.83 4.91 4.94 6.14 10.48 16.23 13.99 7.94 11.36
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.49 0.44 0.42 0.43 0.47 0.49 0.58 0.58 0.54 0.54
Accounts Receivable Turnover		 5.83 6.26 6.45 5.86 6.02 5.85 6.68 6.87 6.28 6.22
Inventory Turnover		 3.34 3.61 4.11 3.44 3.26 3.22 3.65 3.38 2.82 2.93
Fixed Asset Turnover		 3.50 3.65 4.12 4.03 4.09 4.06 4.79 4.82 4.15 4.03
Accounts Payable Turnover		 8.16 8.05 6.93 4.73 4.25 4.17 4.44 4.25 4.04 4.41
Days Sales Outstanding (DSO)		 62.64 58.34 56.62 62.26 60.68 62.43 54.66 53.12 58.16 58.69
Days Inventory Outstanding (DIO)		 109.37 101.00 88.76 106.25 111.89 113.47 100.12 108.02 129.38 124.53
Days Payable Outstanding (DPO)		 44.75 45.33 52.65 77.23 85.89 87.56 82.25 85.95 90.38 82.83
Cash Conversion Cycle (CCC)		 127.26 114.01 92.72 91.27 86.68 88.34 72.53 75.19 97.16 100.39
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 20,810 18,430 48,822 45,868 45,052 44,579 43,840 43,629 46,383 54,197
Invested Capital Turnover		 0.93 1.06 0.81 0.65 0.70 0.77 0.97 1.00 0.89 0.83
Increase / (Decrease) in Invested Capital		 -2,294 -2,380 30,392 -2,954 -816 -473 -739 -211 2,754 7,814
Enterprise Value (EV)		 55,710 49,625 105,991 129,850 154,775 192,505 243,582 189,096 193,196 200,669
Market Capitalization		 56,760 49,162 88,359 115,069 141,446 181,508 236,375 183,040 186,371 195,160
Book Value per Share		 $14.18 $13.95 $17.75 $17.38 $17.58 $18.50 $20.25 $21.04 $22.24 $27.48
Tangible Book Value per Share		 $4.02 $5.65 ($8.39) ($6.65) ($5.16) ($3.24) ($0.10) $1.97 $3.52 $10.33
Total Capital		 30,327 42,723 59,022 50,288 49,440 51,750 54,074 53,678 53,506 62,026
Total Debt		 9,001 22,006 27,924 19,566 18,139 18,747 18,050 16,773 14,679 14,125
Total Long-Term Debt		 5,871 20,681 27,210 19,359 16,661 18,527 17,296 14,522 13,599 12,625
Net Debt		 -1,165 284 17,431 14,583 13,116 10,778 6,985 5,837 6,601 5,272
Capital Expenditures (CapEx)		 1,110 1,121 1,135 1,394 1,638 2,177 1,885 1,777 2,202 2,207
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 1,974 2,666 2,339 1,741 2,142 1,606 1,639 1,816 2,630 3,032
Debt-free Net Working Capital (DFNWC)		 8,099 21,441 11,949 5,827 6,282 8,754 11,888 11,986 9,909 10,999
Net Working Capital (NWC)		 4,969 20,116 11,235 5,620 4,804 8,534 11,134 9,735 8,829 9,499
Net Nonoperating Expense (NNE)		 -2,076 876 -230 597 411 326 184 47 -160 -359
Net Nonoperating Obligations (NNO)		 -516 -2,287 17,724 15,146 13,751 11,576 7,816 6,724 7,556 6,296
Total Depreciation and Amortization (D&A)		 1,472 1,518 3,933 3,310 3,014 3,327 3,538 3,267 3,243 3,218
Debt-free, Cash-free Net Working Capital to Revenue		 9.67% 12.78% 8.54% 5.69% 6.71% 4.64% 3.81% 4.16% 6.56% 7.23%
Debt-free Net Working Capital to Revenue		 39.69% 102.82% 43.63% 19.06% 19.69% 25.29% 27.60% 27.46% 24.71% 26.22%
Net Working Capital to Revenue		 24.35% 96.47% 41.02% 18.38% 15.06% 24.66% 25.85% 22.30% 22.01% 22.64%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 $2.94 $0.94 $0.27 $1.34 $2.07 $2.52 $3.97 $3.94 $3.28 $7.67
Adjusted Weighted Average Basic Shares Outstanding		 1.50B 1.48B 1.74B 1.76B 1.77B 1.77B 1.78B 1.75B 1.74B 1.74B
Adjusted Diluted Earnings per Share		 $2.92 $0.94 $0.27 $1.33 $2.06 $2.50 $3.94 $3.91 $3.26 $7.64
Adjusted Weighted Average Diluted Shares Outstanding		 1.51B 1.48B 1.75B 1.77B 1.78B 1.79B 1.79B 1.76B 1.75B 1.75B
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $2.07 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 1.47B 1.73B 1.75B 1.76B 1.76B 1.77B 1.76B 1.74B 1.74B 1.73B
Normalized Net Operating Profit after Tax (NOPAT)		 2,347 2,276 1,095 2,965 4,098 4,821 7,255 6,980 5,563 4,778
Normalized NOPAT Margin		 11.50% 10.92% 4.00% 9.70% 12.85% 13.93% 16.84% 15.99% 13.87% 11.39%
Pre Tax Income Margin		 15.60% 6.78% 8.15% 9.40% 12.78% 14.36% 19.06% 19.03% 16.61% 16.72%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 19.88 4.05 3.33 3.79 6.43 10.01 16.32 15.56 10.86 12.93
NOPAT to Interest Expense		 14.40 5.28 0.27 2.99 5.59 8.83 13.61 12.51 8.73 23.33
EBIT Less CapEx to Interest Expense		 13.07 1.45 2.08 2.38 4.20 6.03 12.79 12.37 7.40 8.98
NOPAT Less CapEx to Interest Expense		 7.59 2.68 -0.98 1.58 3.36 4.84 10.08 9.32 5.28 19.38
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 32.62% 109.93% 387.63% 83.36% 61.57% 56.95% 45.28% 47.73% 62.14% 28.62%
Augmented Payout Ratio		 83.20% 147.21% 412.16% 93.41% 81.04% 65.92% 77.80% 102.47% 83.58% 38.29%

Quarterly Metrics And Ratios for Abbott Laboratories

This table displays calculated financial ratios and metrics derived from Abbott Laboratories' official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -4.74% -12.01% -18.06% -11.36% -2.56% 1.49% 2.23% 4.00% 4.85% 7.16% 3.95%
EBITDA Growth		 -23.22% -34.14% -36.58% -23.87% -3.57% 22.12% -4.88% -1.08% 8.89% 7.62% 12.21%
EBIT Growth		 -29.51% -43.36% -46.07% -30.96% -5.64% 34.56% -7.25% -1.89% 14.43% 11.26% 22.04%
NOPAT Growth		 -32.63% -49.79% -48.61% -36.43% -2.04% 54.90% -7.14% 4.34% 11.44% 449.64% 6.71%
Net Income Growth		 -31.67% -48.06% -46.14% -31.86% 0.07% 54.31% -7.06% -5.31% 14.62% 478.98% 8.16%
EPS Growth		 -30.77% -46.85% -45.26% -31.58% 1.23% 54.24% -6.67% -5.13% 14.63% 478.02% 8.57%
Operating Cash Flow Growth		 2.92% -24.16% -44.65% -50.08% -32.48% 30.61% -10.32% 62.93% 44.11% -5.60% 38.24%
Free Cash Flow Firm Growth		 -42.99% -55.57% -29.76% -145.43% -203.65% -195.28% -203.50% 158.56% 124.36% 174.49% -488.44%
Invested Capital Growth		 -2.03% -0.48% 0.20% 4.30% 9.01% 6.31% 5.38% 2.15% 2.14% 16.85% 17.97%
Revenue Q/Q Growth		 -7.52% -3.06% -3.41% 2.37% 1.65% 0.97% -2.70% 4.14% 2.49% 3.19% -5.61%
EBITDA Q/Q Growth		 -18.93% -17.53% 10.35% 3.18% 2.68% 4.45% -14.04% 7.30% 13.04% 3.22% -10.37%
EBIT Q/Q Growth		 -24.98% -24.84% 16.45% 5.14% 2.53% 7.18% -19.73% 11.22% 19.58% 4.22% -11.95%
NOPAT Q/Q Growth		 -29.13% -29.37% 24.77% 1.78% 9.21% 11.68% -25.20% 14.37% 16.64% 450.82% -85.48%
Net Income Q/Q Growth		 -28.89% -28.01% 27.59% 4.32% 4.44% 11.00% -23.15% 6.29% 26.42% 460.69% -85.64%
EPS Q/Q Growth		 -28.95% -27.16% 27.12% 4.00% 5.13% 10.98% -23.08% 5.71% 27.03% 459.57% -85.55%
Operating Cash Flow Q/Q Growth		 15.35% -16.33% -50.86% 5.25% 56.03% 61.85% -66.26% 91.22% 38.01% 6.03% -50.59%
Free Cash Flow Firm Q/Q Growth		 73.23% -47.05% -3.91% -151.55% -295.18% 51.33% -4.38% 129.17% 64.40% 48.82% -924.53%
Invested Capital Q/Q Growth		 -4.13% 2.78% 2.48% 3.29% 0.20% 0.24% 1.59% 0.12% 0.18% 14.67% 2.56%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 55.53% 54.48% 55.57% 55.07% 54.60% 55.51% 55.21% 55.64% 55.83% 54.97% 56.86%
EBITDA Margin		 25.54% 21.73% 24.83% 25.03% 25.28% 26.15% 23.10% 23.80% 26.25% 26.26% 24.94%
Operating Margin		 17.00% 12.92% 15.48% 15.45% 16.24% 17.38% 13.91% 16.08% 17.48% 17.41% 16.34%
EBIT Margin		 17.71% 13.74% 16.56% 17.01% 17.15% 18.21% 15.02% 16.05% 18.72% 18.91% 17.64%
Profit (Net Income) Margin		 13.78% 10.24% 13.52% 13.78% 14.16% 15.56% 12.29% 12.55% 15.48% 84.10% 12.79%
Tax Burden Percent		 81.63% 78.26% 84.38% 84.05% 85.94% 88.80% 85.31% 81.02% 84.85% 454.63% 74.52%
Interest Burden Percent		 95.34% 95.24% 96.78% 96.41% 96.03% 96.25% 95.93% 96.52% 97.44% 97.83% 97.32%
Effective Tax Rate		 18.37% 21.74% 15.62% 15.95% 14.06% 11.20% 14.69% 18.98% 15.15% -354.63% 25.48%
Return on Invested Capital (ROIC)		 14.57% 10.09% 12.14% 11.55% 12.57% 13.76% 10.42% 11.37% 13.07% 66.04% 10.04%
ROIC Less NNEP Spread (ROIC-NNEP)		 14.44% 10.27% 12.68% 12.52% 12.84% 13.94% 10.97% 10.76% 13.94% 73.85% 10.91%
Return on Net Nonoperating Assets (RNNOA)		 3.12% 2.05% 2.87% 2.76% 2.64% 2.63% 2.24% 2.29% 2.84% 11.80% 1.81%
Return on Equity (ROE)		 17.70% 12.14% 15.01% 14.31% 15.21% 16.38% 12.66% 13.66% 15.91% 77.83% 11.85%
Cash Return on Invested Capital (CROIC)		 20.69% 16.44% 12.73% 6.92% 2.66% 6.24% 6.68% 9.72% 10.06% 10.40% 9.01%
Operating Return on Assets (OROA)		 10.88% 8.01% 9.30% 9.27% 9.46% 9.89% 8.28% 8.93% 10.54% 10.26% 9.71%
Return on Assets (ROA)		 8.47% 5.97% 7.59% 7.51% 7.81% 8.46% 6.78% 6.98% 8.71% 45.63% 7.04%
Return on Common Equity (ROCE)		 17.59% 12.07% 14.91% 14.22% 15.13% 16.29% 12.58% 13.58% 15.82% 77.42% 11.79%
Return on Equity Simple (ROE_SIMPLE)		 22.11% 0.00% 15.68% 13.88% 13.77% 0.00% 14.51% 14.13% 14.49% 0.00% 27.66%
Net Operating Profit after Tax (NOPAT)		 1,445 1,020 1,273 1,296 1,415 1,581 1,182 1,352 1,577 8,688 1,262
NOPAT Margin		 13.88% 10.11% 13.06% 12.99% 13.95% 15.43% 11.87% 13.03% 14.83% 79.17% 12.18%
Net Nonoperating Expense Percent (NNEP)		 0.13% -0.17% -0.54% -0.97% -0.27% -0.19% -0.55% 0.61% -0.87% -7.81% -0.87%
Return On Investment Capital (ROIC_SIMPLE)		 - 1.90% - - - 2.95% - - - 14.01% 2.02%
Cost of Revenue to Revenue		 44.47% 45.52% 44.43% 44.93% 45.40% 44.49% 44.79% 44.36% 44.17% 45.03% 43.14%
SG&A Expenses to Revenue		 26.23% 29.46% 28.34% 27.46% 26.85% 26.60% 29.70% 28.29% 27.22% 26.49% 29.55%
R&D to Revenue		 7.51% 7.18% 6.71% 7.17% 6.63% 6.84% 6.86% 6.73% 6.70% 6.83% 6.91%
Operating Expenses to Revenue		 38.53% 41.56% 40.08% 39.62% 38.36% 38.13% 41.30% 39.56% 38.35% 37.55% 40.52%
Earnings before Interest and Taxes (EBIT)		 1,844 1,386 1,614 1,697 1,740 1,865 1,497 1,665 1,991 2,075 1,827
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 2,659 2,193 2,420 2,497 2,564 2,678 2,302 2,470 2,792 2,882 2,583
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 4.57 4.99 4.61 4.97 4.37 4.83 5.03 4.57 4.96 4.09 4.69
Price to Tangible Book Value (P/TBV)		 64.10 53.32 41.87 45.28 33.29 30.51 27.39 21.97 22.47 10.90 11.93
Price to Revenue (P/Rev)		 3.62 4.19 4.11 4.59 4.10 4.65 4.84 4.42 4.79 4.65 5.41
Price to Earnings (P/E)		 20.65 26.40 29.41 35.81 31.75 32.57 34.69 32.36 34.24 14.56 16.96
Dividend Yield		 2.00% 1.79% 1.95% 1.84% 2.12% 1.90% 1.85% 2.05% 1.90% 1.96% 1.70%
Earnings Yield		 4.84% 3.79% 3.40% 2.79% 3.15% 3.07% 2.88% 3.09% 2.92% 6.87% 5.90%
Enterprise Value to Invested Capital (EV/IC)		 3.98 4.33 3.97 4.18 3.71 4.17 4.30 3.96 4.32 3.70 4.22
Enterprise Value to Revenue (EV/Rev)		 3.75 4.33 4.28 4.80 4.30 4.82 5.03 4.58 4.95 4.78 5.54
Enterprise Value to EBITDA (EV/EBITDA)		 12.90 15.83 16.83 19.75 17.76 19.02 20.18 18.65 19.91 19.21 21.88
Enterprise Value to EBIT (EV/EBIT)		 17.33 21.78 24.31 29.50 26.69 27.93 29.81 27.59 29.06 27.76 31.06
Enterprise Value to NOPAT (EV/NOPAT)		 21.12 27.09 30.73 38.31 34.31 34.73 37.03 33.74 35.81 15.39 17.93
Enterprise Value to Operating Cash Flow (EV/OCF)		 16.36 19.74 20.50 25.89 26.23 26.61 28.37 23.63 23.37 23.45 26.23
Enterprise Value to Free Cash Flow (EV/FCFF)		 19.02 26.30 31.22 61.63 145.57 68.77 66.11 41.14 43.34 38.38 50.76
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.46 0.45 0.45 0.45 0.41 0.38 0.37 0.37 0.37 0.29 0.27
Long-Term Debt to Equity		 0.43 0.39 0.39 0.39 0.38 0.35 0.32 0.33 0.32 0.26 0.26
Financial Leverage		 0.22 0.20 0.23 0.22 0.21 0.19 0.20 0.21 0.20 0.16 0.17
Leverage Ratio		 2.08 2.05 2.03 1.99 1.97 1.95 1.92 1.90 1.88 1.78 1.75
Compound Leverage Factor		 1.98 1.95 1.96 1.92 1.89 1.88 1.84 1.84 1.84 1.74 1.70
Debt to Total Capital		 31.39% 31.25% 31.22% 31.05% 29.18% 27.43% 27.20% 27.16% 27.23% 22.77% 21.25%
Short-Term Debt to Total Capital		 2.14% 4.19% 4.22% 4.21% 1.97% 2.02% 3.75% 2.97% 3.92% 2.42% 0.81%
Long-Term Debt to Total Capital		 29.25% 27.05% 27.00% 26.84% 27.20% 25.42% 23.45% 24.19% 23.32% 20.35% 20.44%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.40% 0.41% 0.41% 0.42% 0.40% 0.42% 0.43% 0.45% 0.42% 0.38% 0.41%
Common Equity to Total Capital		 68.21% 68.34% 68.37% 68.52% 70.42% 72.15% 72.37% 72.39% 72.35% 76.85% 78.34%
Debt to EBITDA		 1.25 1.40 1.60 1.72 1.61 1.44 1.45 1.47 1.46 1.35 1.23
Net Debt to EBITDA		 0.44 0.49 0.62 0.81 0.80 0.65 0.71 0.66 0.61 0.50 0.51
Long-Term Debt to EBITDA		 1.17 1.22 1.39 1.49 1.50 1.34 1.25 1.31 1.25 1.21 1.19
Debt to NOPAT		 2.05 2.40 2.93 3.34 3.10 2.64 2.67 2.67 2.63 1.08 1.01
Net Debt to NOPAT		 0.72 0.84 1.14 1.57 1.54 1.19 1.30 1.20 1.10 0.40 0.42
Long-Term Debt to NOPAT		 1.91 2.08 2.53 2.89 2.89 2.44 2.30 2.37 2.25 0.97 0.97
Altman Z-Score		 4.21 4.39 4.28 4.55 4.37 4.75 5.00 4.75 4.97 5.05 5.81
Noncontrolling Interest Sharing Ratio		 0.60% 0.60% 0.62% 0.62% 0.57% 0.59% 0.60% 0.61% 0.57% 0.53% 0.55%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 1.86 1.63 1.68 1.64 1.74 1.64 1.60 1.68 1.60 1.67 1.78
Quick Ratio		 1.22 1.06 1.07 1.00 1.04 1.00 0.95 1.02 1.00 1.05 1.09
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 2,326 1,231 1,183 -610 -2,411 -1,173 -1,225 357 587 874 -7,206
Operating Cash Flow to CapEx		 595.29% 381.31% 300.79% 237.28% 335.18% 402.38% 257.54% 367.73% 486.51% 398.33% 292.77%
Free Cash Flow to Firm to Interest Expense		 16.50 8.00 7.73 -3.84 -14.52 -7.38 -8.69 2.55 4.14 6.43 -55.01
Operating Cash Flow to Interest Expense		 19.72 15.10 7.47 7.57 11.31 19.11 7.27 14.00 19.05 21.09 10.82
Operating Cash Flow Less CapEx to Interest Expense		 16.40 11.14 4.99 4.38 7.93 14.36 4.45 10.19 15.13 15.79 7.12
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.61 0.58 0.56 0.55 0.55 0.54 0.55 0.56 0.56 0.54 0.55
Accounts Receivable Turnover		 7.03 6.87 6.29 6.02 6.19 6.28 6.39 6.25 6.08 6.22 6.08
Inventory Turnover		 3.51 3.38 2.99 2.82 2.91 2.82 2.68 2.66 2.72 2.93 2.78
Fixed Asset Turnover		 5.14 4.82 4.56 4.40 4.38 4.15 4.16 4.14 4.09 4.03 4.03
Accounts Payable Turnover		 4.74 4.25 4.14 4.14 4.45 4.04 4.34 4.37 4.58 4.41 4.46
Days Sales Outstanding (DSO)		 51.93 53.12 58.04 60.66 58.95 58.16 57.14 58.37 60.00 58.69 60.05
Days Inventory Outstanding (DIO)		 103.89 108.02 122.06 129.22 125.48 129.38 136.07 137.02 134.12 124.53 131.34
Days Payable Outstanding (DPO)		 77.01 85.95 88.10 88.07 82.01 90.38 84.11 83.47 79.64 82.83 81.85
Cash Conversion Cycle (CCC)		 78.81 75.19 92.00 101.80 102.42 97.16 109.09 111.93 114.47 100.39 109.54
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 42,447 43,629 44,712 46,182 46,273 46,383 47,119 47,177 47,263 54,197 55,587
Invested Capital Turnover		 1.05 1.00 0.93 0.89 0.90 0.89 0.88 0.87 0.88 0.83 0.82
Increase / (Decrease) in Invested Capital		 -881 -211 90 1,906 3,826 2,754 2,407 995 990 7,814 8,468
Enterprise Value (EV)		 168,825 189,096 177,538 192,954 171,780 193,196 202,660 186,711 203,946 200,669 234,741
Market Capitalization		 162,873 183,040 170,724 184,832 163,874 186,371 195,310 179,811 197,435 195,160 228,997
Book Value per Share		 $20.37 $21.04 $21.30 $21.38 $21.60 $22.24 $22.30 $22.60 $22.87 $27.48 $28.14
Tangible Book Value per Share		 $1.45 $1.97 $2.35 $2.35 $2.84 $3.52 $4.10 $4.70 $5.05 $10.33 $11.07
Total Capital		 52,298 53,678 54,132 54,250 53,222 53,506 53,629 54,314 55,007 62,026 62,306
Total Debt		 16,414 16,773 16,900 16,846 15,528 14,679 14,586 14,754 14,979 14,125 13,242
Total Long-Term Debt		 15,297 14,522 14,615 14,562 14,477 13,599 12,576 13,139 12,825 12,625 12,736
Net Debt		 5,743 5,837 6,592 7,892 7,693 6,601 7,117 6,658 6,279 5,272 5,491
Capital Expenditures (CapEx)		 467 610 380 507 560 755 398 533 556 720 484
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 2,690 1,816 2,600 3,284 3,626 2,630 3,714 3,755 3,266 3,032 3,811
Debt-free Net Working Capital (DFNWC)		 12,597 11,986 12,132 11,439 10,673 9,909 10,365 10,974 11,054 10,999 10,655
Net Working Capital (NWC)		 11,480 9,735 9,847 9,155 9,622 8,829 8,355 9,359 8,900 9,499 10,149
Net Nonoperating Expense (NNE)		 9.80 -13 -45 -79 -21 -13 -43 50 -69 -541 -63
Net Nonoperating Obligations (NNO)		 6,563 6,724 7,480 8,778 8,579 7,556 8,076 7,617 7,235 6,296 6,523
Total Depreciation and Amortization (D&A)		 815 807 806 800 824 813 805 805 801 807 756
Debt-free, Cash-free Net Working Capital to Revenue		 5.97% 4.16% 6.26% 8.16% 9.07% 6.56% 9.21% 9.22% 7.92% 7.23% 9.00%
Debt-free Net Working Capital to Revenue		 27.97% 27.46% 29.23% 28.44% 26.71% 24.71% 25.70% 26.95% 26.82% 26.22% 25.16%
Net Working Capital to Revenue		 25.49% 22.30% 23.72% 22.76% 24.08% 22.01% 20.72% 22.98% 21.59% 22.64% 23.97%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.82 $0.59 $0.75 $0.79 $0.82 $0.92 $0.70 $0.74 $0.94 $5.29 $0.76
Adjusted Weighted Average Basic Shares Outstanding		 1.75B 1.75B 1.74B 1.74B 1.74B 1.74B 1.74B 1.74B 1.74B 1.74B 1.74B
Adjusted Diluted Earnings per Share		 $0.81 $0.59 $0.75 $0.78 $0.82 $0.91 $0.70 $0.74 $0.94 $5.26 $0.76
Adjusted Weighted Average Diluted Shares Outstanding		 1.76B 1.76B 1.75B 1.75B 1.75B 1.75B 1.75B 1.75B 1.75B 1.75B 1.75B
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 1.74B 1.74B 1.74B 1.74B 1.74B 1.74B 1.74B 1.74B 1.73B 1.73B 1.74B
Normalized Net Operating Profit after Tax (NOPAT)		 1,445 1,020 1,273 1,296 1,415 1,581 1,182 1,352 1,577 1,338 1,262
Normalized NOPAT Margin		 13.88% 10.11% 13.06% 12.99% 13.95% 15.43% 11.87% 13.03% 14.83% 12.19% 12.18%
Pre Tax Income Margin		 16.89% 13.08% 16.03% 16.40% 16.47% 17.53% 14.41% 15.49% 18.24% 18.50% 17.17%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 13.08 9.00 10.55 10.67 10.48 11.73 10.62 11.89 14.02 15.26 13.95
NOPAT to Interest Expense		 10.25 6.63 8.32 8.15 8.53 9.94 8.39 9.66 11.11 63.88 9.63
EBIT Less CapEx to Interest Expense		 9.77 5.04 8.07 7.48 7.11 6.98 7.79 8.09 10.11 9.96 10.25
NOPAT Less CapEx to Interest Expense		 6.93 2.67 5.84 4.96 5.15 5.19 5.56 5.85 7.19 58.59 5.94
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 41.63% 47.73% 58.01% 66.44% 67.63% 62.14% 64.35% 66.47% 65.30% 28.62% 28.92%
Augmented Payout Ratio		 93.40% 102.47% 92.95% 113.89% 99.65% 83.58% 80.57% 75.29% 86.79% 38.29% 38.91%

Key Financial Trends

Over the past four years, Abbott Laboratories (NYSE: ABT) has demonstrated steady financial performance with growth in revenue, strong operating margins, and disciplined capital management. Here are the key trends and financial highlights based on quarterly income statements, balance sheets, and cash flow statements from Q3 2022 through Q1 2025:

  • Revenue Growth: Operating revenue increased from approximately $9.75 billion in Q1 2023 to about $10.36 billion in Q1 2025, reflecting consistent demand for Abbott's products across segments.
  • Gross Profit Improvement: Gross profit rose from $5.42 billion in Q1 2023 to $5.89 billion in Q1 2025, indicating effective cost management and stable product pricing.
  • Operating Income Growth: Operating income expanded from $1.51 billion in Q1 2023 to $1.69 billion in Q1 2025, demonstrating operational efficiency despite increased SG&A and R&D expenses.
  • Consistent Net Income: Net income remained solid, with $1.32 billion reported in Q1 2025 compared to $1.32 billion in Q1 2023, showing strong profitability maintenance.
  • EPS Stability: Diluted earnings per share stayed stable around $0.75 in Q1 2023 and $0.76 in Q1 2025, supported by moderate share count reductions over time.
  • Strong Operating Cash Flow: Net cash from operating activities was $1.42 billion in Q1 2025, up from $1.15 billion in Q1 2023, reflecting healthy cash generation from core operations.
  • Investment in Growth: Capital expenditures (PP&E purchases) were consistent, around $380-$480 million quarterly, supporting sustained asset base modernization and expansion.
  • Debt Levels Steady: Long-term debt remained relatively flat near $12.7-$14.6 billion, balancing between repayments and issuances, indicating stable leverage.
  • Share Repurchases and Dividends: The company actively repurchased shares ($226 million to $315 million in recent quarters) and maintained steady dividend payouts around $0.55-$0.59 per share quarterly, reflecting shareholder returns focus.
  • Rising SG&A and R&D Expenses: While revenue and operating income grew, SG&A and R&D expenses also increased from about $2.76 billion and $654 million (Q1 2023) to $3.06 billion and $716 million (Q1 2025), which could pressure margins if sales growth slows.

Summary: Abbott Laboratories has shown consistent revenue and profit growth with efficient cash flow generation. The company balances investments in R&D and capital assets with shareholder returns via dividends and share buybacks. Rising operating expenses warrant monitoring but are currently supported by top-line gains. The stable debt profile and strong equity base further contribute to financial resilience. Overall, Abbott remains well positioned for sustainable growth and shareholder value creation.

08/03/25 01:27 PMAI Generated. May Contain Errors.

Frequently Asked Questions About Abbott Laboratories' Financials

When does Abbott Laboratories' financial year end?

According to the most recent income statement we have on file, Abbott Laboratories' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Abbott Laboratories' net income changed over the last 9 years?

Abbott Laboratories' net income appears to be on an upward trend, with a most recent value of $13.40 billion in 2024, rising from $4.42 billion in 2015. The previous period was $5.72 billion in 2023. Find out what analysts predict for Abbott Laboratories in the coming months.

What is Abbott Laboratories' operating income?
Abbott Laboratories' total operating income in 2024 was $6.83 billion, based on the following breakdown:
  • Total Gross Profit: $23.24 billion
  • Total Operating Expenses: $16.42 billion
How has Abbott Laboratories' revenue changed over the last 9 years?

Over the last 9 years, Abbott Laboratories' total revenue changed from $20.41 billion in 2015 to $41.95 billion in 2024, a change of 105.6%.

How much debt does Abbott Laboratories have?

Abbott Laboratories' total liabilities were at $33.51 billion at the end of 2024, a 2.5% decrease from 2023, and a 68.2% increase since 2015.

How much cash does Abbott Laboratories have?

In the past 9 years, Abbott Laboratories' cash and equivalents has ranged from $3.84 billion in 2018 to $18.62 billion in 2016, and is currently $7.62 billion as of their latest financial filing in 2024.

How has Abbott Laboratories' book value per share changed over the last 9 years?

Over the last 9 years, Abbott Laboratories' book value per share changed from 14.18 in 2015 to 27.48 in 2024, a change of 93.8%.


Related Companies

This page (NYSE:ABT) was last updated on 8/3/2025 by MarketBeat.com Staff
From Our Partners
Man Who Called Nvidia at $1.10 Says Buy This Now...
In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...
The Oxford Club | Sponsored
Crypto Income (almost instantly)
How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...
Awesomely, LLC | Sponsored
[No Brainer Gold Play]: “Show me a better investment.”
A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...
Golden Portfolio | Sponsored
Elon’s Secret Social Security Bombshell
To All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...
Banyan Hill Publishing | Sponsored
Investigating the Most Controversial Stock on Earth
Tesla’s wild price swings may not be random after all. Hedge fund veteran Larry Benedict has uncovered a st...
Brownstone Research | Sponsored
Trump’s national nightmare is here
Porter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...
Porter & Company | Sponsored
The Trump Dump is starting; Get out of stocks now?
The first 365 days of the Trump presidency… Will be the best time to get rich in American history.
Paradigm Press | Sponsored
Trump set to Boost Social Security Checks by 400%?
If you're collecting or planning to collect social security... You should see this presentation about Presi...
InvestorPlace | Sponsored